|
Doxycycline and OA Progression Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Doxycycline and OA Progression conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Doxycycline and OA Progression Clinical research trials and Doxycycline and OA Progression healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Doxycycline and OA Progression. Doxycycline and OA Progression Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Doxycycline and OA Progression clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Doxycycline and OA Progression condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Doxycycline and OA Progression  Doxycycline and OA Progression
Doxycycline and OA Progression
For Condition: Osteoarthritis
Status: Completed
Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) , National Institute on Aging (NIA)
Synopsis: This study will determine whether doxycycline decreases the severity or rate of progression of osteoarthritis (OA) in the knee. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most popular agents used to treat OA, but elderly women, in whom OA is especially common, are at greatest risk of developing serious side effects from NSAIDs. Our study targets overweight middle-aged women who have OA in one knee. Half of the 432 study participants will receive the treatment (doxycycline) and half will receive a placebo (inactive pill). Treatment with doxycycline (or placebo) will last 30 months, and participants and researchers will not know who is receiving doxycycline and who is receiving placebo until the end of the study. We will look for narrowing of the joint space in the knee that was not affected by OA at the start of the study. Joint space narrowing is a sign of OA. We will also use questionnaires to evaluate participants' symptoms and functioning.
Details: This study is a double-blind, multicenter randomized controlled trial of doxycycline on osteoarthritis (OA) progression. Our previous research suggests that doxycycline might help prevent or slow OA development by reducing breakdown of cartilage in joints. The target population is one that is at high risk for the development of bilateral knee OA: overweight middle-aged women with unilateral knee OA at baseline. We hypothesize that doxycycline will decrease the severity or rate of progression of OA. We are recruiting 432 study participants across six clinical centers and randomizing them to treatment or placebo groups (N=216/group). Participants will receive either doxycycline (treatment) or placebo for 30 months. We will use several strategies to maximize compliance with the study medications and retention of participants in the study, including a "faintness-of-heart" test, which will be used at the outset to eliminate people unlikely to comply, and use of a computerized medicine cap to provide information on compliance with the prescribed dosing regimen between visits. These strategies will permit study personnel to aim their efforts to enhance compliance at those participants who can best benefit from these efforts. The primary outcome variable is minimum joint space width (or joint space narrowing, JSN) in the medial tibiofemoral compartment of the knee that is normal at baseline. In addition, we will examine changes in an algofunctional index (WOMAC), global arthritis activity, general health status (SF-36), and use of health services in the two treatment groups.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Efficacy Study
Minimum Age/Maximum Age: 45 Years/64 Years
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: - Women 45-64 years of age. - Upper tertile of sex-, age- and race-adjusted norms for body mass index. - Unilateral knee OA at baseline. - Postmenopausal status or otherwise incapable of childbearing. - Ability to ambulate (move about) independently without assistive devices. - Ability to read and write in English or Spanish and give informed consent. Exclusion Criteria: - Premenopausal status (unless subject has had a hysterectomy). - Current use of any investigational drug. - Significant hematologic, renal, hepatic or cardiovascular disease (but not including mild/moderate hypertension) or any other serious medical condition that might preclude the subject's ability to participate fully in the project, keep clinic appointments, etc. - Prior surgery (including arthroscopy) of the contralateral knee. - Significantly abnormal laboratory values at the time of enrollment. - Pigmented villonodular synovitis of the knee. - Synovial chondromatosis. - Charcot arthropathy. - A known "secondary" cause of OA, including acute or chronic infectious OA; crystal-induced arthritis; systemic inflammatory connective tissue disease (e.g., rheumatoid arthritis, systemic lupus erythematosus); osteonecrosis; Paget's disease; or metabolic diseases, such as hemochromatosis, Wilson's disease, or ochronosis. Chondrocalcinosis, however, will not be an exclusion criterion. - Conditions other than knee OA which limit lower extremity function and mobility and/or would confound the evaluation of knee pain and function (e.g., clinically significant spinal or hip arthritis, painful or dysfunctional feet, peripheral vascular disease, lumbar radiculopathy, stroke, etc.). - Steroid injection into either knee within past 3 months. - A history of photosensitivity (sensitivity to light) or any other adverse reaction to a tetracycline. - Failure to pass a "faintness-of-heart" test (pre-randomization compliance test). - Prior chronic use of tetracycline (e.g., for severe acne). - Severe OA (Kellgren and Lawrence Grade IV) of the index knee. - Salicylate use, with a mean dose >2g/d. - Institutionalization.
Total Enrollment: 432
Location and Contact Information:
Overall Study Official:
KennethBrandt, Principal Investigator, Indiana University School of Medicine
Indiana University Medical Center
Indianapolis, Indiana, 46202-5100
United States
Arthritis Research Center Foundation
Wichita, Kansas, 67214
United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213-3221
United States
University of Arizona Arthritis Center
Tucson, Arizona, 85724
United States
University of Alabama at Birmingham
Birmingham, Alabama, 35294
United States
Northwestern University Medical Center
Chicago, Illinois, 60611
United States
Additional Information:
Study ID Numbers: NIAMS-027; R01 AR43348
Study Start Date: September 1996
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000403
Other Osteoarthritis Studies:
1. Impact of Exercise on Older Persons with Osteoarthritis
2. Genetic and Immune Studies of Rheumatoid Arthritis and Related Conditions
3. Aerobic Exercise Intervention for Knee Osteoarthritis
4. Efficacy of Acupuncture with Physical Therapy for Knee Osteo-Arthritis
5. Muscle Strengthening Device for Knee Osteoarthritis
Related Studies:
Other Osteoarthritis Clinical Trials
Other Arizona Clinical Trials
Other Tucson Clinical Trials
Doxycycline and OA Progression
|
|
|
|
|
|
|
|
